Texas Reaches $45M Settlement With Gilead Over Allegations That Patient-Support Programs Improperly Encouraged Prescriptions for Drugs

The state of Texas secured a $45 million settlement from Gilead Sciences Inc. over allegations that its patient-support programs improperly encouraged prescriptions for drugs covered by Medicaid. This case highlights both how patient-support services can draw scrutiny when they provide something of value to prescribers, even when no money changes hands, as well as the ongoing role of state attorneys general in health care enforcement.

Read more at Regulatory Oversight